Invention Grant
- Patent Title: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
-
Application No.: US16195446Application Date: 2018-11-19
-
Publication No.: US10823727B2Publication Date: 2020-11-03
- Inventor: Theresa Rosario-Jansen , David Erick Wright
- Applicant: Horizon Pharma Rheumatology LLC
- Applicant Address: US IL Lake Forest
- Assignee: Horizon Pharma Rheumatology LLC
- Current Assignee: Horizon Pharma Rheumatology LLC
- Current Assignee Address: US IL Lake Forest
- Agent Dennis A. Bennett; Chris Marion; Stephanie M. Greer
- Main IPC: C12Q1/62
- IPC: C12Q1/62 ; G01N33/53 ; G01N33/68 ; A61K9/00 ; A61K38/44 ; A61K47/60 ; A61P19/02
Abstract:
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Public/Granted literature
Information query
